A survey of 539 people with Lynch syndrome in Germany reveals that few use aspirin for cancer prevention, despite high interest in other preventive measures like mRNA vaccines.
Key facts
- •Lynch syndrome causes a hereditary predisposition to colorectal and other cancers.
- •The survey was conducted by researchers from the University of Bonn and the UKB in collaboration with the organization SemiColon.
- •Researchers identified an implementation gap between existing scientific evidence and medical counseling.
- •The CaPP3 study suggests a 100 mg daily dose of aspirin may be a better-tolerated option than higher doses.
- •Most survey participants expressed a willingness to accept risks associated with clinical trials and potential side effects.
A study published in The Lancet Gastroenterology & Hepatology indicates that fewer than 7% of people with Lynch syndrome use acetylsalicylic acid specifically for cancer prevention. While the CAPP2 and CaPP3 studies suggest the drug can reduce colorectal cancer risk, researchers found a significant gap between scientific evidence and actual patient use.
By the numbers
Survey Findings on Aspirin Use
The survey, conducted between December 2025 and February 2026, included 539 participants with Lynch syndrome. While 97% of respondents were familiar with screening recommendations and nearly all undergo regular colonoscopies, only 10.4% reported taking acetylsalicylic acid, with just 6.9% using it specifically for cancer prevention. Patients cited a lack of engagement with the topic, concerns about side effects, and uncertainty regarding scientific evidence as primary reasons for not using the medication.
Interest in New Preventive Approaches
Despite low aspirin usage, the study found high openness to innovative prevention. Approximately 75% of respondents expressed interest in participating in a study for a preventive mRNA cancer vaccine, a figure that rose to 80% after receiving additional information. Over 92% indicated they would want to receive such a vaccine if it were approved in the future.
Scientific Context
The CAPP2 study previously demonstrated that a 600 mg daily dose of acetylsalicylic acid could reduce long-term colorectal cancer risk in this high-risk group. The more recent CaPP3 study suggests that a lower 100 mg daily dose may offer similar benefits with fewer side effects, such as bleeding complications. Researchers emphasize that while these findings are promising, they should be interpreted with caution as formal equivalence criteria were not met in all analyses.
Advertisement
This article was independently rewritten by ManyPress editorial AI from reporting originally published by Medical Xpress.
